Crohn's Disease
VIDEO: Subcutaneous guselkumab induction achieves clinical remission in Crohn’s disease
PHILADELPHIA — Subcutaneous guselkumab outperformed placebo and, as with IV administration, appears to have “profound induction effects” on both clinical remission and endoscopic response in Crohn’s disease, a presenter told Healio.
‘No clear efficacy benefit’ to combining bezlotoxumab with FMT in IBD, recurrent C. diff
PHILADELPHIA — Bezlotoxumab in combination with fecal microbiota transplantation did not further reduce recurrence of Clostridioides difficile infection in patients with inflammatory bowel disease, according to data presented here.
‘No meaningful difference’: Zymfentra monotherapy as effective as combined therapy for IBD
PHILADELPHIA — Zymfentra as monotherapy was no more effective when combined with immunosuppressants for maintenance therapy in patients with Crohn’s disease or ulcerative colitis, according to post-hoc analysis presented here.
VIDEO: Primary sclerosing cholangitis increases risk for CRC, even among those without IBD
PHILADELPHIA — Primary sclerosing cholangitis is an independent risk factor for colorectal cancer, with an “almost three-times higher” risk among patients without inflammatory bowel disease vs. the general population, a researcher reported.
FDA expands approval of Stelara biosimilar Selarsdi to include UC, Crohn’s disease
The FDA approved the Stelara biosimilar, Selarsdi, as a 130 mg/26 mL single-dose IV infusion for adult patients with Crohn’s disease and ulcerative colitis, Alvotech and Teva Pharmaceuticals announced in a press release.
Mirikizumab bests ustekinumab in histologic response at week 52 in Crohn’s
More patients with moderate to severe Crohn’s disease achieved histologic response at week 52 with mirikizumab vs. ustekinumab, regardless of prior biologic exposure, according to data presented at UEG Week.
Rinvoq outperforms placebo in drainage resolution, closure in perianal fistulizing Crohn’s
Treatment with Rinvoq resulted in higher rates of closure of external openings and drainage resolution vs. placebo in perianal fistulizing Crohn’s disease, according to pooled data from the U-EXCEL, U-EXCEED and U-ENDURE trials.
Imuldosa snags FDA approval as fifth Stelara biosimilar in mounting market logjam
The FDA has approved the Stelara biosimilar, Imuldosa, for Crohn’s disease, ulcerative colitis and all other indications of the reference product, and the latest addition to the Stelara biosimilar bottleneck set to release in 2025.
JAK inhibitors: ‘A valuable addition’ to the IBD treatment portfolio
This month’s Healio Exclusive highlights the efficacy of Janus kinase inhibitors in the management of ulcerative colitis and Crohn’s disease.
‘Don’t shy away’ from JAKs in IBD: Monitor patient outcomes, understand potential risks
Despite an existing class-wide black box warning, 45% of health care providers felt cardiovascular concerns related to Janus kinase inhibitors “were irrelevant” to patients with inflammatory bowel disease, according to survey results.